NCT02526979View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Overactive BladderNeurogenic Detrusor Overactivity
Interventions
DRUG

mirabegron

oral

Trial Locations (3)

8200

Site DK45001, Aarhus

9000

Site DK45002, Aalborg

04-730

Site PL48001, Warsaw

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02526979 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) | Biotech Hunter | Biotech Hunter